Metastatic Non-Small Cell Lung Carcinoma treated with immunotherapy+ chemotherapy: a case of dissociated response?
DOI:
https://doi.org/10.32932/gecp.2022.09.024Keywords:
Non-Small Cell Lung Carcinoma, Immunotherapy, Response AssessmentAbstract
Assessment of response to systemic therapy can be challenging in mNSCLC, especially with immunotherapy, due to the possibility of atypical response patterns. We report a case of metastatic lung adenocarcinoma under immunotherapy and chemotherapy with an apparent response dissociated in a pulmonary nodule, whose biopsy of the non-responsive lesion revealed a histological diagnosis different from the primary tumour. When there is a discrepancy in the type of response to systemic treatment of two different target lesions, it should be considered the possibility of a second primary tumour. The histopathological and/or molecular diagnosis confirmation is crucial for (re)staging, treatment decisions, and patient prognosis.Downloads
References
Borcoman E, Kanjanapan Y, Champiat S, et al. Novel patterns of response under immunotherapy. Ann Oncol, 2019; 30(3): 385-96. doi:10.1093/annonc/mdz003.
Zhou L, Zhang M, Li R, Xue J, Lu Y. Pseudoprogression and hyperprogression in lung cancer: a comprehensive review of the literature . J Cancer Res Clin Oncol, 2020; 46(12):3269-79. https://doi.org/10.1007/s00432-020-03360-1
Humbert O, Chardin D. Dissociated Response in Metastatic Cancer: An Atypical Pattern Brought Into the Spotlight With Immunotherapy. Front. Oncol, 2020; 10:566297. doi: 10.3389/fonc.2020.566297
Eichhorn F, Winter H. How to handle oligometastatic disease in nonsmall cell lung cancer. Eur Respir Rev, 2021; 30: 200234 [https://doi.org/10.1183/16000617.0234-2020].
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 2009; 45(2): 228-47. doi: 10.1016/j.ejca.2008.10.026.
Decazes P, Bohn P. Immunotherapy by Immune Checkpoint Inhibitors and Nuclear Medicine Imaging: Current and Future Applications. Cancers, 2020; 12(2):371. doi:10.3390/cancers12020371
Tazdait M, Mezquita L, Lahmar J et al. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: comparison of RECIST 1.1, irRECIST and iRECIST criteria. Eur J Cancer, 2018; 88: 38-47. doi: 10.1016/j.ejca.2017.10.017.
Humbert O, Cadour N, Paquet M, et al. 18FDG PET/CT in the early assessment of non-small cell lung cancer response to immunotherapy: frequency and clinical significance of atypical evolutive patterns. Eur J Nucl Med Mol Imaging, 2020; 47(5):1158–67. doi: 10.1007/s00259-019-04573-4
Seymour L, Bogaerts J, Perrone A, et al. iRECIST: Guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol, 2017;18(3): e143-e152. doi:10.1016/S1470-2045(17)30074-8.
Patel PH, Palma D, McDonald F, Tree AC. The Dandelion Dilemma Revisited for Oligoprogression: Treat the Whole Lawn or Weed Selectively? Clin. Oncol, 2019; 31(12):824-33. https://doi.org/10.1016/j.clon.2019.05.015.
Rheinheimer S, Heussel CP, Mayer P, et al. Oligo-progressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 Inhibitors. Cancers, 2020; 12(4):1046. doi:10.3390/cancers12041046.
Martini N, Melamed MR. Multiple primary lung cancers. J Thorac Cardiovasc Surg, 1975; 70:606-12.
Zhao L, Liu C, Xie G. Multiple Primary Lung Cancers: A New Challenge in the Era of Precision Medicine. Cancer Manag Res, 2020;12:10361–10374.
Schneider F, Derrick V, Davison JM, et al. Morphological and molecular approach to synchronous non-small cell lung carcinomas: impact on staging. Mod Pathol, 2016; 29(7):735-42. doi:10.1038/modpathol.2016.66.
Loukeri AA, Kampolis CF, Ntokou A, Tsoukalas G, Syrigos K. Metachronous and Synchronous Primary Lung Cancers: Diagnostic Aspects, Surgical Treatment, and Prognosis. Clin Lung Cancer, 2015; 16(1):15-23. http://dx.doi.org/10.1016/j.cllc.2014.07.001.
Ambrogi MC, Fanucchi O, Dini P, Melfi F, Davini F, Lucchi M, et al. Wedge resection and radiofrequency ablation for stage I nonsmall cell lung cancer. Eur Respir J, 2015;45(4):1089-97. doi: 10.1183/09031936.00188014.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Author(s) (or their employer(s)) and THORAC 2024
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
